- Home
- AREN vs NERV Comparison
AREN vs NERV Comparison
Compare AREN & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AREN | NERV |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.6M | 189.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AREN | NERV |
|---|---|---|
| Price | $3.35 | $4.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $4.00 |
| AVG Volume (30 Days) | 64.2K | ★ 76.5K |
| Earning Date | 11-13-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $142,815,000.00 | N/A |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | $13.81 | N/A |
| P/E Ratio | $5.12 | ★ N/A |
| Revenue Growth | ★ 6.72 | N/A |
| 52 Week Low | $1.20 | $1.15 |
| 52 Week High | $10.05 | $12.46 |
Technical Indicators
Market Signals| Indicator | AREN | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 50.21 |
| Support Level | $3.19 | $4.19 |
| Resistance Level | $4.04 | $4.99 |
| Average True Range (ATR) | 0.20 | 0.39 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 4.78 | 43.55 |
Price Performance
Historical ComparisonAbout AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.